Kornimate/medical-research-clean huggingface dataset:
exploratory study of apple watch electrocardiographic diagnostic performance enhanced by an artificial intelligence algorithm

Conditions: Atrial Fibrillation

Summary: this observational exploratory prospective study will evaluate the performance on an artificial intelligence (ai) solution interpreting ecg (electrocardiogram) collected from an apple watch (ai-aw) in the detection of atrial fibrillation (af)

after being informed about the study, participants hospitalized for ablation or cardioversion or having a cardiac rhythm consultation at the investigational center will have apple watch ecg recordings done simultaneously with 12-lead ecg measurements performed in accordance with the existing in-stay subject monitoring protocol. ai-aw will be compared to standard manual 12-lead ecg reviewed by cardiologists for af detection.

Eligibility criteria:
inclusion criteria: * patient aged 22 or older, able and willing to participate in the study * patient admitted to hospital for ablation, cardioversion or cardiac electrophysiological exploration or who come for regular rhythmology consultations * patient who has read the information note and has given his or her consent before any procedure related to the study * patient affiliated to social security exclusion criteria: * pregnant or breastfeeding women * patient with a pacemaker, implantable defibrillator or cardiac resynchronisation therapy device. * subject related to the investigator or any other staff member directly involved in the conduct of the study * patient incapable of giving consent, minor or adult patient protected by law
fermented food-supplemented diet in ulcerative colitis

Conditions: Inflammatory Bowel Diseases; Diet Modification; Ulcerative Colitis

Summary: the purpose of this study is to see how a diet that supplements fermented foods effects inflammation and quality of life in patients with mild to moderate ulcerative colitis (uc). there is a paucity of research and an enormous need for better understanding of diet and intestinal inflammation. fermented food have been shown to positively influence inflammatory cytokines and intestinal microbial diversity in healthy volunteers.


Eligibility criteria:
inclusion criteria: * written informed consent * male or female subjects, ≥18 years of age * confirmed diagnosis of uc * symptomatic disease defined as partial mayo score 2 to 7 (inclusive) * elevated fecal calprotectin exclusion criteria: * women who are pregnant, nursing or expect to be pregnant * intolerance to fermented food * individuals with a body mass index (bmi) lower than 18 * individuals diagnosed with a serious medical condition (unless approved in writing by a physician) * individuals who have been severely weakened by a disease or medical procedure * individuals with more than mild-moderate cardiovascular disease or life-threatening cancer (as determined by patient's physician) unless approved by a physician * individuals with history of severe cardiac disease (particularly uncompensated congestive heart failure nyha grade 2 or more or lvef \< 40%) * history of relevant intestinal surgery such as total or hemi-colectomy, proctocolectomy, stoma. complications of disease such as extraintestinal manifestations (eims) are not automatically considered exclusion criteria. appropriate medical treatment for uc and/or eims will not be withheld.

Keywords: ibd ulcerative colitis uc diet fermented food
safety, tolerability, pharmacokinetics and pharmacodynamics of acz885 in patients with rheumatoid arthritis with ongoing treatment with methotrexate

Conditions: Rheumatoid Arthritis

Summary: this study assessed the long-term safety and tolerability of acz885 in patients with rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or improvement of joint structure and bone mineral density, and long term maintenance of health-related quality of life.


Eligibility criteria:
inclusion criteria: * male and female patients aged 18.5 - 65/75 years (depending on the dose group). * diagnosis of rheumatoid arthritis (acr 1987 revised classification for criteria for ra) with a disease duration of at least 6 months prior to randomization. * active disease at screening and baseline evaluation (same evaluator) ) with more than 6 tender and 6 swollen joints of 28 examined (including any effused joint) and either a) westergren erythrocyte sedimentation (esr) ≥ 28 mm/hour, or b) crp ≥ 6 mg/l. * patients should have failed at least 1 dmard in the past, but should not be deemed "refractory to all therapies" * patients should have a current treatment regimen of ≥ 15 mg methotrexate/week and with the current dose stable for approximately 3 months. * patients were required to have an otherwise stable ra therapeutic regimen, consisting of either a stable dose of nsaids and/or a stable dose of oral corticosteroids (prednisone or equivalent \< 10 mg daily) for at least 4 weeks prior to randomization. exclusion criteria: * previous treatment with anti-tnf-α antibody therapy (or other biological therapy) within appropriate timeframe (considering the half life of the compound) * patients who have received intra-articular or systemic corticosteroid injections having been required for treatment of acute ra flare (not being part of a regular therapeutic regimen) within four weeks prior to randomization or require narcotic analgesics other than those accepted by the investigator for analgesia (e.g., codeine, tramadol, dextropropoxyphene) other protocol-defined inclusion/exclusion criteria may apply.

Keywords: rheumatoid arthritis anti-interleukin-1 beta acz885
effect of cavotricuspid isthmus ablation in patients without history of typical flutter during ablation

Conditions: Paroxysmal Atrial Fibrillation

Summary: it has been demonstrated that successful cavotricuspid isthmus ablation may be effective in preventing paroxysmal atrial fibrillation. however, the effectiveness of only isthmus ablation on atrial fibrillation itself is unclear.

researchers hypothesized that an organized activation pattern around the tricuspid annulus during atrial fibrillation indicated a mother reentrant circuit that could be terminated by a cavocaval isthmus ablation, thus preventing atrial fibrillation. the objectives of the present study were to evaluate the effectiveness of isthmus ablation in preventing atrial fibrillation and to identify predictors of its success.

Eligibility criteria:
inclusion criteria: * scheduled ablation for paroxysmal atrial fibrillation exclusion criteria: * typical atrial flutter * history of artificial tricuspid valve surgery

Keywords: fibrillation catheter ablation
life quality study for pfapa patient

Conditions: PFAPA Syndrome

Summary: this cohort study aims to assess the quality of life (or welfare) related to the health of children and adolescents with an non genetics auto-inflammatory disease pfapa or marshall syndrome to compare it to children or adolescents with recurrent fever genetics of familial mediterranean fever (fmf) in order to improve their overall care.


Eligibility criteria:
inclusion criteria: * pfapa syndrome patients or fmf patients exclusion criteria: * participation refusal
diagnosing deep-vein thrombosis early in critically ill patients

Conditions: Deep Vein Thrombosis; Pulmonary Embolism

Summary: the detect randomized controlled trial addresses the question of whether surveillance ultrasound in critically ill patients by facilitating dvt detection reduces the incidence of pe and lowers all-cause 90-day mortality. the primary outcome is 90-day all-cause mortality.

this is an open-label multicenter multinational randomized-controlled trial. all patients admitted to icu will be screened within the first 48 hours of icu admission for eligibility. subjects who meet all criteria for enrollment will be randomized via a password-protected, secure website using a variable-size block concealed computer-generated randomization procedure. patients will be allocated to twice weekly bilateral lower limb ultrasound or standard care (control) in a 1:1 ratio.

Eligibility criteria:
inclusion criteria 1. medical, surgical or trauma icu patients ≥18 years old. 2. patients who are expected to stay in the icu more than 2 calendar days (unlikely to be discharged out of icu on the day of admission or on the next day). exclusion criteria 1. patients with dvt or pe diagnosed within the last year. 2. patients receiving chronic systemic anticoagulation. 3. patients who have received up to the time of icu admission or are receiving therapeutic doses of anticoagulation with ufh, lmwh, or other anticoagulants. 4. inability or contraindication to obtain adequate ultrasound on the lower extremities (burns in the lower extremities, lacerations, active skin infection, \& ischemic limb in the legs, large dressings in the thighs that prevent adequate ultrasounds or amputated foot or leg on one or two sides) 5. patients with inferior vena cava (ivc) filter. 6. known or suspected pregnancy. 7. limitation of life support, life expectancy \<7 days or palliative care. 8. previously enrolled in detect trial within the last 180 days. 9. enrolled in another trial for which co-enrolment is not approved.
licensing flu shot study

Conditions: Flu

Summary: the mailer will encourage all employees of one of evive's partner companies to attend an on-site free flu shot clinic they are offering in the fall of 2011. the research will examine differences in follow-through on getting a flu shot at an on-site clinic among the targeted population during the \~1 month period when clinics are being offered (following the mailing) as a function of experimental condition.


Eligibility criteria:
inclusion criteria: * employee at partner corporation exclusion criteria: * employee already received a flu shot this season

Keywords: flu shot
disruptions of brain networks and sleep by electroconvulsive therapy

Conditions: Treatment Resistant Depression

Summary: electroconvulsive therapy (ect) alleviates treatment-resistant depression (trd) through repeated generalized seizures. the goal of this study is to evaluate how ect impacts sleep-wake regulation and efficiency of information transfer in functional networks in different states of arousal.

graph-based network analyses of electroencephalographic (eeg) signals allow characterization of functional networks. the robustness of local networks to disruption is quantified as local efficiency (elocal), while network integration is quantified as global information transfer (eglobal). aim 1: assess relationships between sleep slow-wave activity (swa) and awake elocal over the course of ect. aim 2: quantify relationships between depression severity and awake elocal over the course of ect.

Eligibility criteria:
inclusion criteria: * referral for initial ect index course for treatment-resistant depression (trd), unipolar major depressive disorder or bipolar depression. historic failure of response or remission to at least two antidepressant medications of sufficient dose and duration will be used for trd diagnostic. exclusion criteria: * diagnoses of schizophrenia or schizoaffective disorders. * subjects who are unable to tolerate the dreem device for sleep recordings will be excluded from the study.
investigation of psychometric properties of the euroqol eq-5d-5l in patients with carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the purpose of this study is to determine how appropriate and practically is the eq-5d questionnaire in use on patients with carpal tunnel syndrome undergoing surgery along the change of quality of life.

carpal tunnel syndrome (cts) is one of the most indications in hand surgery. to rate surgery's outcome, hand-specific instruments like the michigan hand questionnaire (mhq) are used as well as questionnaires which refers to the quality of life (qol). in clinical daily grind, the sf-12 or the eq-5d are common instruments to gain information about the patient's qol. at the time, there is no current evidence available while using standardized questionnaires like the eq-5d to capture the change in qol in patients with cts undergoing surgery. it would be interesting to assert that the investigation offers results about the patient's qol and its change. therefore, the aim of the study is to investigate the psychometric properties of the eq-5d on patients with cts undergoing surgery.

Eligibility criteria:
inclusion criteria: * age over 18 years * diagnosed cts * planned surgical decompression of the carpal tunnel * signed informed consent exclusion criteria: * additional simultaneously performed hand surgery of the affected limb * recurrent surgery on the already involved hand * the other hand is already included in the study * disease, which do not allow appropriated analysis of data like central-neurological, psychiatric or metabolic disease * legal incompetence

Keywords: carpal tunnel syndrome quality of life eq-5d sf-12 michigan hand questionnaire
clinical trial on the efficacy of intralesional triamcinolone versus candida albicans antigen in treating alopecia areata

Conditions: Alopecia Areata

Summary: the efficacy of two intralesional treatment modalities for alopecia areata will be determined. thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. a comparison will be made between the effectiveness of intralesional triamcinolone (standard first-line treatment) and intralesional candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.


Eligibility criteria:
inclusion criteria: * diagnosis of alopecia areata * salt score of less than 50% extension * has not received any topical or systemic treatment in the last month * signed informed consent exclusion criteria: * any skin condition on the scalp (infectious, inflammatory or neoplastic) that could modify the clinical of trichoscopic features * pregnancy or breast-feeding * patients in medications that could cause hair loss as side-effects
which physical activity influences achilles tendon blood flow the most?

Conditions: Physical Activity

Summary: previous studies have shown that a decreased blood flow is a risk factor in the occurrence of achilles tendon (at) injuries. based on the current literature, no consensus was reached as to the most solid warming-up of the at. therefore, knowledge about activities which increase blood flow in the at could be useful in the development of a solid warming-up programme for the at. the aim of this investigation was to define the influence of different kinds of physical activity on the vascularisation of the at in a healthy asymptomatic population. subjects performed five activities in randomized order: running, static stretch, dynamic stretch, cycling and rope skipping. the vascularisation of the at of the dominant limb was measured with the non-invasive oxygen-to-see (o2c) device. blood flow was measured before, immediately after, five and ten minutes after activity to investigate the duration of the vascular response to activity.


Eligibility criteria:
inclusion criteria: * no history of achilles tendon complaints * healthy and active adolescents exclusion criteria: * history of achilles tendon pain or current complaints * not healthy or not active population * children

Keywords: achilles tendon warming-up vascularisation physical activity oxygen-to-see (o2c)
strain-counterstrain treatment of piriformis pain

Conditions: Low Back Pain, Mechanical; Piriformis Syndrome; Somatic Dysfunction of Sacral Region (Finding)

Summary: the purpose of this investigator-initiated study is to provide an efficient and non-invasive treatment option for pain caused by the piriformis muscle.

there are two arms to the study: treatment and sham. the treatment group will receive strain-counterstrain for the piriformis muscle. the sham group will receive strain-counterstrain treatment for the hamstring muscle. there will be two treatments, 1-2 weeks apart ideally. participants will fill out the oswestry disability index questionnaire before the first treatment and after the second treatment (which is 1-2 weeks after the first treatment). participants will also identify pain using the visual analog scale (vas) before and after each treatment. participants will identify pain at rest prior to treatment using vas. participant will then identify pain at the start of treatment while pressure is applied to the piriformis muscle (4.5kg/cm2) and post treatment while pressure is applied to the piriformis muscle (4.5 kg/cm2). an algometer will be used pre and post each treatment (2 treatments that are 1-2 weeks apart) to objectively measure any change in pain pressure threshold.

Eligibility criteria:
inclusion criteria: * 18 to 65 years of age * tender point (or trigger point) in piriformis muscle determined by physical exam exclusion criteria: * less than 45 degrees of active hip flexion, less than 5 degrees of active hip internal rotation or less than 30 degrees of active hip external rotation, on side of affected piriformis * unable to lay prone * non-english speaker * inability to attend 2 sessions within the same month * active cancer * pregnant * diagnosis of lumbar radiculopathy * greater than grade 1 lumbar spondylolisthesis * presence of lumbar region pars defect * receiving massage, acupuncture, chiropractic treatments, osteopathic treatments during study period.
re-model dabigatran etexilate 150mg or 220mg once daily (o.d.) versus (v.s.) enoxaparin 40mg o.d. for prevention of thrombosis after knee surgery

Conditions: Arthroplasty, Replacement, Knee; Thromboembolism

Summary: a phase iii, randomised, parallel-group, double-blind, active controlled study to investigate the ef ficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsule s \[150 or 220 mg once daily starting with a half dose (i.e.75 or 110 mg) on the day of surgery\] comp ared to subcutaneous enoxaparin 40 mg once daily for 6 to 10 days, in prevention of venous thromboem bolism in patients with primary elective total knee replacement surgery. re-model (thromboembolism prevention after knee surgery)


Eligibility criteria:
inclusion criteria inclusion criteria (selected): * patients (18 years or older) scheduled to undergo a primary, unilateral, elect ive total knee replacement * written informed consent exclusion criteria exclusion criteria (selected): * patients with an excessive risk of bleeding, for example because of history of bleeding diathesis major surgery or trauma within the last 3 months history of haemorrhagic stroke or any of the following intracranial pathologies: bleeding, neoplasm, arteriovenous (av) malformation or aneurysm clinically relevant bleeding or gastric / duodenal ulcer within the last 6 months treatment with anticoagulants within 7 days prior to joint replacement surgery or anticipated need during the study treatment period thrombocytopenia. * active malignant disease or current cytostatic treatment * known severe renal insufficiency * liver disease expected to have any potential impact on survival, or elevated aspartate aminotransferase (ast) or alanine transaminase (alt) \> 2x upper limit of normal * recent unstable cardiovascular disease or history of myocardial infarction within the last 3 months * pre-menopausal women who are pregnant or nursing, or are of child-bearing pote ntial and are not practising or do not plan to continue practising acceptable me thods of birth control * allergy to radio opaque contrast media or iodine, heparins (incl. heparin indu ced thrombocytopenia) or dabigatran * contraindications to enoxaparin * participation in a clinical trial during the last 30 days
safety of tobramycin inhalation powder (tip) vs tobramycin solution for inhalation in patients with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: this study compares the safety of the tobramycin solution for inhalation with the tobramycin dry powder formulation, used with a simple inhaler


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of cystic fibrosis * male and female patients at least 6 years of age at the time of screening. * forced expiratory volume in one second (fev1) at screening must be at least 25% and less than or equal to 75% of normal predicted values for age, sex, and height based on knudson criteria. * pseudomonas aeruginosa, a type of bacteria, must be present in a sputum/deep-throat cough swab culture (or bronchoalveolar lavage \[bal\]) within 6 months prior to screening and in the sputum/ deep-throat cough swab culture at the screening visit. * able to comply with all protocol requirements. * clinically stable in the opinion of the investigator. * use of an effective means of contraception in females of childbearing potential. * provide written informed consent, health authority portability and accountability act (hipaa) authorization (where applicable), and assent (as appropriate) prior to the performance of any study-related procedure. exclusion criteria: * history of sputum culture or deep-throat cough swab (or bal) culture yielding burkholderia cepacia (b cepacia), a type of bacteria, within 2 years prior to screening and/or sputum culture yielding b cepacia at screening. * coughing up more than 60 cc of blood from the respiratory tract at any time within 30 days prior to study drug administration. * known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics. * females who are pregnant (positive pregnancy test), lactating, or are planning to become pregnant during the study. * history of hearing loss or chronic ringing in the ears deemed clinically significant by the investigator. * use of systemic or inhaled antipseudomonal antibiotics within 28 days prior to study drug administration. * use of loop diuretics within 7 days prior to study drug administration. * use of any investigational treatment within 28 days prior to study drug administration. * initiation of treatment with chronic macrolide therapy, dornase alpha treatment or inhaled corticosteroids within 28 days prior to study drug administration (patients may be taking these therapies at the time of enrollment, but they must have initiated treatment more than 28 days prior to study drug administration). other protocol-defined inclusion/exclusion criteria may apply

Keywords: tobramycin